In addition, to investigate the potential of ME1 as a target for tumor immunotherapy, we analyzed the overall survival rates of patients exhibiting high versus low expression of ME1 following treatment with anti-PD1, anti-PDL1, or anti-CTLA4 therapies. The gene discussed is CD274; the disease is neoplasm.